PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Daratumumab plus anti-CD20 rescues refractory recurrent FSGS after transplant

daratumumabanti-CD38rituximabobinutuzumabanti-CD20recurrent FSGSfocal segmental glomerulosclerosiskidney transplantationantinephrin antibodyplasma cell depletionretrospective cohortnephrotic syndrome Nephrology

Background Information

Can dual antibody therapy offer a lifeline for transplant patients with recurrent FSGS?

Recurrent focal segmental glomerulosclerosis (rFSGS) after kidney transplantation is difficult to treat, and effective therapies are needed. In a study of 17 patients, 41% achieved complete remission and 24% achieved partial remission with combined anti-CD38 and anti-CD20 therapy. The combination therapy showed promising remission rates and reduced proteinuria in rFSGS, highlighting potential for wider clinical use pending further trials. Combined anti-CD38 and anti-CD20 therapy may offer new hope for managing refractory rFSGS post-kidney transplant.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Leon J, Ducrocq E, Lafargue MC, Bertrand D, Maigret L, Zaidan M, Colin AM, Thervet E, Durrbach A, Kamar N, Schvartz B, Bouvier N, Mazloum M, Bennani HN, Guezennec M, Es-Saleh D, Troger A, Burger C, Le Stang MB, Roger C, Hullekes F, Aubert O, Zuber J, Riella LV, Audard V, Anglicheau D

Citation: Leon J, Ducrocq E, Lafargue MC, et al. Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS. Kidney international reports. 2026;11(9):106668. doi:10.1016/j.ekir.2026.106668

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.